This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tresiba

Novo Nordisk A/S

Drug Names(s): Degludec, Soluble insulin basal analogue (SIBA), NN1250, IDeg

Description: Degludec (NN1250) is a neutral, soluble, long-acting insulin analogue with a flat and predictable profile providing more than 24-hour coverage by once-daily injection.

Degludec will be provided in a new and improved disposable pen, called the PDS290 pen.


Tresiba News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug